HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kratom Advocates Urge Industry Compliance, FDA And DEA Compassion

This article was originally published in The Rose Sheet

Executive Summary

Now that FDA has completed its evaluations of two compounds in kratom – mitragynine and 7-hydroxymitragynine – that DEA has proposed to schedule as controlled substances, researchers who attest to the ingredient's safety and its value in helping opioid abusers through withdrawal or as a natural pain reliever or mood enhancer say time could be running short to convince federal officials against ending consumer access to kratom products due to fear that the ingredient is an opioid.

You may also be interested in...



Opioid Abuse Treatment Claims Prompt FDA Warnings To Two Kratom Marketers

As in previous warnings to kratom supplement marketers linked to opioid addiction treatment claims, FDA tells Cali Botanicals and Kratom NC that HHS in 2017 found opioid abuse was nationwide public health emergency and FDA is targeting products that without approval claim to diagnose, mitigate, prevent, treat or cure opioid addiction. Contract manufacturer Somlabs' GMP problems also were identified in FDA's latest warning letters.

FDA Consumer Health Market Oversight Stays In Spotlight In Gottlieb's Final Week

In four days before Scott Gottlieb's stint as commissioner ended, FDA announced official start of initiative to consider regulatory pathways to make CBD compliant as a dietary ingredient, launched another shot across kratom sector's bow and noted more examples of e-cigarette marketers crossing regulatory lines.

Gottlieb Leaves FDA Feeling Good About Generic Approvals, But Concerned About Innovative Competition

In interview with the Pink Sheet, US FDA Commissioner Scott Gottlieb offers a final reflection of his time as commissioner.

Related Content

Topics

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel